沙库巴曲缬沙坦联合阿托伐他汀对冠心病合并心力衰竭患者的临床效果与安全性评价
Clinical efficacy and safety evaluation of combination therapy with sacubitril-valsartan and atorvastatin in patients with coronary heart disease and heart failure
张勇1
作者信息
摘要
目的 探讨沙库巴曲缬沙坦联合阿托伐他汀对冠心病合并心力衰竭患者的临床效果与安全性.方法 120 例冠心病合并心力衰竭患者,随机分为观察组和对照组,每组 60 例.观察组接受沙库巴曲缬沙坦和阿托伐他汀联合治疗,对照组接受马来酸依那普利和阿托伐他汀联合治疗.比较两组治疗后心功能分级,治疗效果,治疗前后收缩压(SBP)、舒张压(DBP),不良反应发生情况.结果 观察组治疗后心功能分级优于对照组,但差异无统计学意义(P>0.05).观察组总有效率 76.67%明显高于对照组 56.67%,差异有统计学意义(P<0.05).治疗后,观察组SBP和DBP分别为(116.25±16.35)、(79.58±8.36)mm Hg(1 mm Hg=0.133 kPa),明显低于对照组的(125.36±15.36)、(86.63±8.25)mm Hg,差异有统计学意义(P<0.05).两组不良反应发生率比较差异无统计学意义(P>0.05).结论 沙库巴曲缬沙坦与他汀类药物联合治疗冠心病合并心力衰竭患者的临床效果良好,安全性较高,可以为医生提供更准确的指导,助其做出适当的治疗选择.
Abstract
Objective To explore the clinical efficacy and safety of combination therapy with sacubitril-valsartan and atorvastatin in patients with coronary heart disease and heart failure.Methods A total of 120 patients with coronary heart disease and heart failure were randomly divided into an observation group and a control group,with 60 cases in each group.The observation group received the combined treatment of sacubitril-valsartan and atorvastatin,and the control group received the combined treatment of enalapril maleate and atorvastatin.The heart function grading after treatment,treatment effect,and systolic blood pressure(SBP)and diastolic blood pressure(DBP)before and after treatment,and occurrence of adverse reactions were compared between the two groups.Results The heart function grading of the observation group was better than that of the control group after treatment,but the difference was not statistically significant(P>0.05).The total effective rate of the observation group was 76.67%,which was significantly higher than 56.67%of the control group,and the difference was statistically significant(P<0.05).After treatment,SBP and DBP in the observation group were(116.25±16.35)and(79.58±8.36)mm Hg(1 mm Hg=0.133 kPa),which were significantly lower than(125.36±15.36)and(86.63±8.25)mm Hg in the control group.The difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of sacubitril-valsartan and statins in the treatment of patients with coronary heart disease and heart failure has good clinical effect and high safety,which can provide doctors with more accurate guidance to help them make appropriate treatment choices.
关键词
心力衰竭/冠心病/沙库巴曲缬沙坦/阿托伐他汀/临床效果/安全性Key words
Heart failure/Coronary heart disease/Sacubitril-valsartan/Atorvastatin/Clinical effect/Safety引用本文复制引用
出版年
2024
NETL
NSTL
维普
万方数据